liraglutide ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
glucagon-like peptide (GLP) analogues and agonists 4164 204656-20-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • saxenda
  • liraglutide [rDNA origin]
  • liraglutide rDNA origin
  • liraglutide [rNDA origin] injection
  • liraglutide
  • NN2211
  • victoza
  • liraglutide recombinant
An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN.
  • Molecular weight: 3751.26
  • Formula: C172H265N43O51
  • CLOGP:
  • LIPINSKI: None
  • HAC: 94
  • HDO: 54
  • TPSA: 1513.76
  • ALOGS:
  • ROTB: 130

Drug dosage:

DoseUnitRoute
40 U P
1.50 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 6 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.01 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
CL (Clearance) 0.01 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 8.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 20, 2010 PMDA Novo Nordisk Pharma Ltd
June 30, 2009 EMA
Jan. 25, 2010 FDA NOVO NORDISK INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pancreatitis 2264.11 14.58 788 21258 48267 63418709
Pancreatitis acute 690.68 14.58 283 21763 26883 63440093
Nausea 562.39 14.58 1031 21015 853440 62613536
Pancreatic carcinoma 426.50 14.58 142 21904 7486 63459490
Diabetic ketoacidosis 361.28 14.58 165 21881 20340 63446636
Vomiting 324.18 14.58 642 21404 558975 62908001
Lipase increased 288.88 14.58 114 21932 9786 63457190
Blood glucose increased 286.06 14.58 235 21811 83521 63383455
Eructation 172.14 14.58 75 21971 8258 63458718
Injection site urticaria 171.44 14.58 88 21958 13985 63452991
Injection site rash 152.78 14.58 90 21956 18719 63448257
Abdominal pain 148.02 14.58 319 21727 293137 63173839
Cholelithiasis 145.10 14.58 121 21925 43804 63423172
Injection site erythema 143.19 14.58 160 21886 83014 63383962
Weight decreased 143.15 14.58 304 21742 276494 63190482
Pancreatic carcinoma metastatic 135.59 14.58 44 22002 2134 63464842
Diabetes mellitus inadequate control 129.77 14.58 75 21971 15051 63451925
Glycosylated haemoglobin increased 124.06 14.58 68 21978 12330 63454646
Hypoglycaemia 123.54 14.58 127 21919 59938 63407038
Injection site pruritus 114.44 14.58 107 21939 45009 63421967
Diarrhoea 109.05 14.58 513 21533 714853 62752123
Ketoacidosis 109.01 14.58 45 22001 4333 63462643
Blood glucose decreased 105.02 14.58 74 21972 20878 63446098
Euglycaemic diabetic ketoacidosis 102.58 14.58 41 22005 3633 63463343
Lactic acidosis 99.40 14.58 92 21954 38195 63428781
Dehydration 94.81 14.58 195 21851 173159 63293817
Medullary thyroid cancer 91.35 14.58 20 22026 201 63466775
Papillary thyroid cancer 91.25 14.58 33 22013 2223 63464753
Amylase increased 89.99 14.58 44 22002 6301 63460675
Thyroid mass 83.64 14.58 37 22009 4221 63462755
Injection site reaction 73.51 14.58 96 21950 58428 63408548
Acute kidney injury 70.31 14.58 226 21820 263189 63203787
Weight loss poor 69.55 14.58 23 22023 1184 63465792
Adenocarcinoma pancreas 68.01 14.58 22 22024 1056 63465920
Abdominal pain upper 63.33 14.58 186 21860 206258 63260718
Thyroid neoplasm 60.40 14.58 29 22017 3990 63462986
Drug ineffective 60.28 14.58 176 21870 1044589 62422387
Systemic lupus erythematosus 57.06 14.58 4 22042 208914 63258062
Thyroid cancer 56.74 14.58 31 22015 5580 63461396
Decreased appetite 56.07 14.58 203 21843 250849 63216127
Impaired gastric emptying 55.30 14.58 38 22008 10294 63456682
Glossodynia 50.10 14.58 3 22043 178873 63288103
Joint swelling 48.11 14.58 27 22019 327639 63139337
Drug dose titration not performed 46.45 14.58 14 22032 531 63466445
Constipation 45.31 14.58 176 21870 224767 63242209
Injection site haematoma 43.50 14.58 28 22018 6804 63460172
Reversible cerebral vasoconstriction syndrome 42.45 14.58 20 22026 2638 63464338
Pancreatic neoplasm 42.12 14.58 14 22032 732 63466244
Arthropathy 41.24 14.58 15 22031 234777 63232199
Flatulence 40.60 14.58 55 21991 34647 63432329
Cholecystitis 39.99 14.58 37 22009 15340 63451636
Abdominal distension 39.91 14.58 91 21955 86524 63380452
Infusion related reaction 39.36 14.58 18 22028 245503 63221473
Pain 38.86 14.58 130 21916 740498 62726478
Pyrexia 38.68 14.58 65 21981 470413 62996563
Treatment failure 37.98 14.58 11 22035 199032 63267944
Drug intolerance 37.86 14.58 31 22015 308630 63158346
Rheumatoid arthritis 35.70 14.58 22 22024 253797 63213179
Pericarditis 34.56 14.58 3 22043 131576 63335400
Pancreatic enzymes increased 34.04 14.58 12 22034 750 63466226
Therapeutic product effect decreased 32.82 14.58 13 22033 193174 63273802
Cholecystitis acute 32.01 14.58 25 22021 8235 63458741
Pancreatic mass 31.72 14.58 12 22034 917 63466059
Hyperglycaemia 31.43 14.58 54 21992 41813 63425163
Neutropenia 31.02 14.58 11 22035 174994 63291982
Injection site pain 30.67 14.58 107 21939 129693 63337283
Drug titration error 29.44 14.58 11 22035 812 63466164
Pancreatic cyst 28.78 14.58 13 22033 1557 63465419
Palpitations 25.81 14.58 92 21954 112678 63354298
Mental disability 25.64 14.58 6 22040 83 63466893
Febrile neutropenia 25.62 14.58 5 22041 118444 63348532
Glycosylated haemoglobin decreased 25.62 14.58 9 22037 557 63466419
Goitre 25.20 14.58 19 22027 5942 63461034
Pancreatitis necrotising 24.66 14.58 12 22034 1700 63465276
Infection 24.56 14.58 26 22020 229147 63237829
Completed suicide 24.41 14.58 10 22036 145663 63321313
General physical health deterioration 23.73 14.58 21 22025 201381 63265595
Renal failure 23.60 14.58 92 21954 117560 63349416
Swelling 23.57 14.58 37 22009 275341 63191635
Bile duct stone 23.32 14.58 15 22031 3641 63463335
Ductal adenocarcinoma of pancreas 23.07 14.58 6 22040 131 63466845
Disease progression 23.01 14.58 7 22039 122751 63344225
Hypoglycaemic unconsciousness 22.84 14.58 9 22037 768 63466208
Haemoglobin decreased 22.79 14.58 11 22035 145474 63321502
Blood glucose abnormal 22.50 14.58 20 22026 7872 63459104
Helicobacter infection 22.12 14.58 3 22043 92782 63374194
Wound 21.79 14.58 15 22031 163248 63303728
Blister 21.61 14.58 9 22037 129805 63337171
Maternal exposure during pregnancy 21.38 14.58 27 22019 220035 63246941
Toxicity to various agents 21.37 14.58 33 22013 247217 63219759
Bile acid malabsorption 21.35 14.58 6 22040 177 63466799
Stomatitis 20.96 14.58 11 22035 138714 63328262
Pancreatic operation 20.90 14.58 3 22043 0 63466976
Huerthle cell carcinoma 20.90 14.58 3 22043 0 63466976
Lack of satiety 20.90 14.58 3 22043 0 63466976
Musculoskeletal stiffness 20.86 14.58 20 22026 184598 63282378
C-reactive protein increased 20.48 14.58 4 22042 94703 63372273
Injection site bruising 20.37 14.58 45 22001 41865 63425111
Injection site nodule 20.27 14.58 14 22032 3821 63463155
Genotype drug resistance test positive 20.04 14.58 7 22039 426 63466550
Glomerular filtration rate decreased 19.98 14.58 24 22022 13417 63453559
Incision site swelling 19.97 14.58 6 22040 225 63466751
White blood cell count decreased 19.62 14.58 12 22034 139092 63327884
Blood calcitonin increased 19.43 14.58 4 22042 29 63466947
Gastritis 19.21 14.58 41 22005 37262 63429714
Pancytopenia 19.14 14.58 5 22041 96928 63370048
Increased appetite 19.12 14.58 20 22026 9610 63457366
Cholangiocarcinoma 19.12 14.58 9 22037 1185 63465791
Hepatic steatosis 18.89 14.58 35 22011 28734 63438242
Aerococcus urinae infection 18.82 14.58 3 22043 3 63466973
Injection site swelling 18.69 14.58 47 21999 47525 63419451
Pneumonia 18.30 14.58 89 21957 456678 63010298
Pancreatic pseudocyst 17.83 14.58 7 22039 591 63466385
Cholecystectomy 17.42 14.58 20 22026 10657 63456319
Impaired healing 17.24 14.58 7 22039 102535 63364441
Dysgeusia 17.16 14.58 45 22001 46665 63420311
Breast cancer 17.15 14.58 46 22000 48337 63418639
Anaemia 17.08 14.58 49 21997 293381 63173595
Malignant neoplasm progression 16.67 14.58 4 22042 82117 63384859
Benign neoplasm of thyroid gland 16.52 14.58 8 22038 1121 63465855
Anuria 16.39 14.58 21 22025 12530 63454446
Biliary colic 16.34 14.58 12 22034 3605 63463371
Injection site cyst 16.27 14.58 4 22042 69 63466907
Death 16.14 14.58 71 21975 374310 63092666
Diabetic retinopathy 15.97 14.58 10 22036 2317 63464659
Gastroenteritis 15.79 14.58 31 22015 26559 63440417
Discomfort 15.77 14.58 21 22025 167353 63299623
Metabolic alkalosis 15.77 14.58 11 22035 3050 63463926
Somnambulism 15.71 14.58 14 22032 5529 63461447
Hepatic enzyme increased 15.63 14.58 29 22017 202299 63264677
Diabetic neuropathy 15.36 14.58 12 22034 3952 63463024
Lower respiratory tract infection 15.33 14.58 14 22032 132293 63334683
Thrombocytopenia 15.25 14.58 18 22028 151139 63315837
Imminent abortion 15.21 14.58 3 22043 17 63466959
Arthralgia 15.11 14.58 126 21920 569584 62897392
Diabetic ketosis 14.87 14.58 5 22041 271 63466705
Gastrooesophageal reflux disease 14.70 14.58 69 21977 95570 63371406

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pancreatitis 1772.19 15.40 661 15024 38230 34903016
Pancreatitis acute 516.86 15.40 252 15433 27889 34913357
Pancreatic carcinoma 420.49 15.40 156 15529 8745 34932501
Nausea 343.69 15.40 573 15112 339335 34601911
Diabetic ketoacidosis 305.54 15.40 153 15532 17879 34923367
Pancreatic carcinoma metastatic 225.49 15.40 74 15611 2866 34938380
Lipase increased 214.62 15.40 98 15587 9318 34931928
Blood glucose increased 188.16 15.40 188 15497 66530 34874716
Vomiting 166.89 15.40 352 15333 247269 34693977
Glycosylated haemoglobin increased 137.33 15.40 77 15608 11283 34929963
Diabetes mellitus inadequate control 132.89 15.40 80 15605 13384 34927862
Adenocarcinoma pancreas 111.08 15.40 36 15649 1338 34939908
Weight decreased 102.96 15.40 237 15448 176064 34765182
Cholelithiasis 98.07 15.40 79 15606 21069 34920177
Abdominal pain 93.35 15.40 218 15467 163400 34777846
Eructation 88.54 15.40 43 15642 4688 34936558
Amylase increased 84.71 15.40 45 15640 5923 34935323
Diarrhoea 81.79 15.40 368 15317 389544 34551702
Lactic acidosis 78.28 15.40 87 15598 34685 34906561
Injection site rash 72.50 15.40 36 15649 4117 34937129
Acute kidney injury 66.93 15.40 292 15393 304696 34636550
Hypoglycaemia 66.70 15.40 101 15584 54539 34886707
Papillary thyroid cancer 64.30 15.40 20 15665 649 34940597
Toxicity to various agents 62.76 15.40 8 15677 200354 34740892
Pancreatitis necrotising 60.60 15.40 28 15657 2730 34938516
Ketoacidosis 60.23 15.40 32 15653 4211 34937035
Abdominal pain upper 56.60 15.40 109 15576 71381 34869865
Thyroid cancer 52.99 15.40 22 15663 1658 34939588
Medullary thyroid cancer 46.12 15.40 9 15676 35 34941211
Weight loss poor 46.04 15.40 12 15673 202 34941044
Metastases to liver 43.08 15.40 41 15644 13622 34927624
Injection site haematoma 41.97 15.40 19 15666 1766 34939480
Respiratory tract haemorrhage 41.30 15.40 17 15668 1253 34939993
Pancreatitis chronic 40.83 15.40 20 15665 2220 34939026
Pancreatic neoplasm 39.50 15.40 15 15670 893 34940353
Thyroid mass 39.33 15.40 13 15672 514 34940732
Febrile neutropenia 39.30 15.40 7 15678 136842 34804404
Injection site erythema 37.87 15.40 41 15644 15858 34925388
Dyspepsia 36.69 15.40 62 15623 36670 34904576
Injection site pruritus 36.48 15.40 28 15657 6955 34934291
Neutropenia 35.50 15.40 13 15672 156765 34784481
Gastrooesophageal reflux disease 35.25 15.40 62 15623 37862 34903384
Dehydration 34.32 15.40 132 15553 129837 34811409
Pancreatic pseudocyst 33.31 15.40 13 15672 834 34940412
Pneumonia 33.10 15.40 71 15614 362556 34578690
Pancreatic mass 32.49 15.40 13 15672 891 34940355
Death 32.29 15.40 83 15602 397966 34543280
Product use in unapproved indication 31.65 15.40 7 15678 117492 34823754
Blood glucose decreased 31.29 15.40 34 15651 13203 34928043
Decreased appetite 30.92 15.40 152 15533 166240 34775006
Cholangiocarcinoma 30.59 15.40 14 15671 1335 34939911
Abdominal discomfort 30.01 15.40 76 15609 59759 34881487
Pancreatic carcinoma stage IV 29.52 15.40 13 15672 1132 34940114
Drug ineffective 29.37 15.40 106 15579 456645 34484601
Tonsillar ulcer 29.30 15.40 8 15677 162 34941084
Constipation 28.25 15.40 129 15556 136853 34804393
Cholecystectomy 28.16 15.40 17 15668 2853 34938393
Diabetic metabolic decompensation 27.00 15.40 14 15671 1752 34939494
Pyrexia 25.79 15.40 71 15614 332942 34608304
Thyroid neoplasm 25.32 15.40 9 15676 444 34940802
Thrombocytopenia 25.10 15.40 20 15665 156227 34785019
White blood cell count decreased 25.08 15.40 6 15679 95439 34845807
Ketosis 24.49 15.40 9 15676 489 34940757
Blood calcitonin increased 24.44 15.40 5 15680 26 34941220
Platelet count decreased 23.79 15.40 12 15673 119705 34821541
Glycosylated haemoglobin decreased 22.82 15.40 8 15677 379 34940867
Flatulence 22.80 15.40 37 15648 21161 34920085
Disease progression 22.75 15.40 10 15675 108067 34833179
Pancreatic enzymes increased 22.13 15.40 9 15676 643 34940603
Thyroid adenoma 21.83 15.40 4 15681 10 34941236
Injection site reaction 21.72 15.40 28 15657 13005 34928241
Euglycaemic diabetic ketoacidosis 21.54 15.40 15 15670 3207 34938039
Pancreatic cyst 20.49 15.40 9 15676 779 34940467
Acinar cell carcinoma of pancreas 20.13 15.40 3 15682 0 34941246
Injection site urticaria 19.63 15.40 12 15673 2060 34939186
Cholecystitis chronic 19.44 15.40 9 15676 881 34940365
Extrasystoles 19.25 15.40 15 15670 3808 34937438
Ludwig angina 19.13 15.40 6 15679 200 34941046
Skin wound 18.86 15.40 7 15678 391 34940855
Malignant neoplasm progression 18.76 15.40 8 15677 88038 34853208
Impaired gastric emptying 18.37 15.40 14 15671 3439 34937807
Pancreatectomy 18.18 15.40 4 15681 31 34941215
Supraventricular extrasystoles 18.18 15.40 14 15671 3494 34937752
Follicular thyroid cancer 18.05 15.40 3 15682 3 34941243
Joint swelling 17.31 15.40 3 15682 59887 34881359
Ductal adenocarcinoma of pancreas 17.27 15.40 4 15681 40 34941206
Gallbladder enlargement 17.26 15.40 9 15676 1139 34940107
Catheter site cellulitis 17.17 15.40 5 15680 129 34941117
Breath odour 16.32 15.40 8 15677 889 34940357
Injection site atrophy 16.17 15.40 4 15681 54 34941192
Drug dose titration not performed 16.15 15.40 6 15679 336 34940910
Cholecystitis acute 16.02 15.40 17 15668 6422 34934824
Gallbladder disorder 15.80 15.40 17 15668 6525 34934721
Hyperglycaemia 15.64 15.40 46 15639 39434 34901812

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pancreatitis 2294.96 13.57 880 28074 67695 79647739
Pancreatitis acute 933.02 13.57 423 28531 49181 79666253
Nausea 636.01 13.57 1191 27763 956005 78759429
Diabetic ketoacidosis 587.96 13.57 274 28680 33848 79681586
Pancreatic carcinoma 535.09 13.57 197 28757 13380 79702054
Vomiting 386.47 13.57 785 28169 665043 79050391
Lipase increased 336.48 13.57 149 28805 16317 79699117
Blood glucose increased 328.63 13.57 297 28657 114678 79600756
Pancreatic carcinoma metastatic 235.11 13.57 77 28877 3676 79711758
Diabetes mellitus inadequate control 212.95 13.57 124 28830 24140 79691294
Eructation 192.07 13.57 89 28865 10820 79704614
Lactic acidosis 189.62 13.57 176 28778 70183 79645251
Glycosylated haemoglobin increased 183.90 13.57 104 28850 19156 79696278
Cholelithiasis 180.46 13.57 151 28803 52513 79662921
Weight decreased 172.84 13.57 391 28563 354807 79360627
Diarrhoea 171.63 13.57 701 28253 879788 78835646
Abdominal pain 171.19 13.57 412 28542 389157 79326277
Ketoacidosis 169.90 13.57 74 28880 7780 79707654
Hypoglycaemia 148.96 13.57 184 28770 101410 79614024
Acute kidney injury 148.24 13.57 469 28485 518935 79196499
Adenocarcinoma pancreas 144.86 13.57 46 28908 1987 79713447
Injection site erythema 123.35 13.57 147 28807 78050 79637384
Euglycaemic diabetic ketoacidosis 120.98 13.57 56 28898 6788 79708646
Injection site urticaria 119.05 13.57 68 28886 12758 79702676
Papillary thyroid cancer 118.60 13.57 42 28912 2544 79712890
Amylase increased 116.47 13.57 64 28890 11145 79704289
Injection site rash 98.03 13.57 68 28886 17886 79697548
Decreased appetite 90.90 13.57 302 28652 342116 79373318
Injection site pruritus 88.18 13.57 92 28862 42191 79673243
Medullary thyroid cancer 86.40 13.57 20 28934 251 79715183
Pancreatitis necrotising 85.10 13.57 37 28917 3871 79711563
Injection site haematoma 83.77 13.57 39 28915 4788 79710646
Blood glucose decreased 81.21 13.57 71 28883 26163 79689271
Dehydration 80.73 13.57 235 28719 247952 79467482
Abdominal pain upper 72.84 13.57 212 28742 223607 79491827
Toxicity to various agents 60.96 13.57 39 28915 421501 79293933
Weight loss poor 59.72 13.57 21 28933 1245 79714189
Joint swelling 57.02 13.57 17 28937 288629 79426805
Pancreatic neoplasm 56.58 13.57 21 28933 1455 79713979
Thyroid mass 53.44 13.57 27 28927 3963 79711471
Neutropenia 53.21 13.57 19 28935 287691 79427743
Drug ineffective 53.00 13.57 208 28746 1080705 78634729
Febrile neutropenia 52.70 13.57 10 28944 230989 79484445
Injection site reaction 51.29 13.57 80 28874 54705 79660729
Thyroid neoplasm 50.10 13.57 24 28930 3140 79712294
Hyperglycaemia 48.98 13.57 90 28864 70245 79645189
Impaired gastric emptying 46.87 13.57 35 28919 10318 79705116
Constipation 46.69 13.57 215 28739 282835 79432599
Flatulence 46.58 13.57 67 28887 42657 79672777
Pyrexia 45.63 13.57 113 28841 678596 79036838
Treatment failure 44.38 13.57 5 28949 170481 79544953
Drug abuse 44.35 13.57 4 28950 162687 79552747
Pancreatic pseudocyst 43.22 13.57 17 28937 1380 79714054
Cholangiocarcinoma 42.72 13.57 20 28934 2486 79712948
Infusion related reaction 41.22 13.57 16 28938 230221 79485213
Cholecystitis acute 40.81 13.57 36 28918 13415 79702019
Abdominal distension 40.48 13.57 115 28839 119535 79595899
Drug dose titration not performed 40.38 13.57 14 28940 796 79714638
Respiratory tract haemorrhage 38.85 13.57 17 28937 1806 79713628
Pancreatitis chronic 36.47 13.57 21 28933 3998 79711436
Dyspepsia 35.35 13.57 103 28851 108584 79606850
Thyroid cancer 34.88 13.57 23 28931 5565 79709869
Glycosylated haemoglobin decreased 34.48 13.57 12 28942 690 79714744
White blood cell count decreased 33.84 13.57 13 28941 188275 79527159
Reversible cerebral vasoconstriction syndrome 33.26 13.57 18 28936 3039 79712395
Thrombocytopenia 32.58 13.57 29 28925 265230 79450204
Completed suicide 32.50 13.57 25 28929 245742 79469692
Bile duct stone 32.47 13.57 22 28932 5567 79709867
Ketosis 32.38 13.57 13 28941 1113 79714321
Pneumonia 32.26 13.57 127 28827 660119 79055315
Pancreatic mass 31.73 13.57 14 28940 1517 79713917
Contraindicated product administered 31.60 13.57 9 28945 157529 79557905
Pain 31.53 13.57 140 28814 703662 79011772
Drug intolerance 31.11 13.57 30 28924 264089 79451345
Platelet count decreased 30.96 13.57 16 28938 194648 79520786
Rheumatoid arthritis 29.13 13.57 20 28934 208450 79506984
Cholecystitis 28.98 13.57 38 28916 22174 79693260
Leukopenia 28.90 13.57 4 28950 116509 79598925
Disease progression 28.09 13.57 16 28938 184346 79531088
Death 27.64 13.57 109 28845 566405 79149029
Haemoglobin decreased 27.62 13.57 24 28930 222095 79493339
Blood glucose abnormal 27.60 13.57 26 28928 10540 79704894
Arthropathy 27.51 13.57 15 28939 177096 79538338
Glossodynia 26.96 13.57 3 28951 103334 79612100
Pancreatic carcinoma stage IV 26.91 13.57 14 28940 2184 79713250
Pancreatic enzymes increased 26.74 13.57 12 28942 1353 79714081
Gastrooesophageal reflux disease 26.73 13.57 91 28863 104155 79611279
Metastases to liver 26.01 13.57 41 28913 28273 79687161
Pemphigus 25.71 13.57 3 28951 99579 79615855
Pancreatic cyst 25.45 13.57 13 28941 1952 79713482
Drug titration error 25.29 13.57 11 28943 1151 79714283
Therapeutic product effect decreased 25.28 13.57 14 28940 163849 79551585
Neutrophil count decreased 23.84 13.57 3 28951 93956 79621478
Tonsillar ulcer 23.63 13.57 8 28946 423 79715011
Malignant neoplasm progression 23.43 13.57 10 28944 135980 79579454
Anaemia 23.40 13.57 83 28871 444932 79270502
Injection site pain 23.15 13.57 101 28853 129737 79585697
Blood calcitonin increased 23.11 13.57 5 28949 45 79715389
Arthralgia 23.08 13.57 118 28836 571685 79143749
C-reactive protein increased 23.03 13.57 9 28945 129018 79586416
Injection site hypersensitivity 22.82 13.57 12 28942 1913 79713521
Ductal adenocarcinoma of pancreas 21.74 13.57 6 28948 158 79715276
Diabetic metabolic decompensation 21.49 13.57 14 28940 3318 79712116
Breath odour 21.33 13.57 11 28943 1685 79713749
Goitre 21.30 13.57 17 28937 5522 79709912
Glomerular filtration rate decreased 21.03 13.57 33 28921 22669 79692765
Benign neoplasm of thyroid gland 20.91 13.57 9 28945 918 79714516
Product contamination with body fluid 20.76 13.57 3 28951 0 79715434
Pleural effusion 20.20 13.57 14 28940 145248 79570186
Thyroid cyst 20.15 13.57 7 28947 400 79715034
Bile acid malabsorption 20.02 13.57 6 28948 213 79715221
Injection site nodule 19.89 13.57 14 28940 3766 79711668
Injection site irritation 19.86 13.57 14 28940 3776 79711658
Increased appetite 19.66 13.57 23 28931 11955 79703479
Gastroenteritis 19.32 13.57 40 28914 34042 79681392
Pericarditis 19.05 13.57 7 28947 104229 79611205
Hypoglycaemic unconsciousness 18.81 13.57 9 28945 1174 79714260
Cholecystectomy 18.72 13.57 20 28934 9412 79706022
Aerococcus urinae infection 18.69 13.57 3 28951 3 79715431
Ludwig angina 18.63 13.57 6 28948 271 79715163
Cancer surgery 18.36 13.57 8 28946 841 79714593
Hyperlipasaemia 18.31 13.57 9 28945 1245 79714189
Musculoskeletal stiffness 18.24 13.57 22 28932 174986 79540448
Hyperkalaemia 18.16 13.57 86 28868 114312 79601122
Incision site swelling 18.09 13.57 6 28948 298 79715136
Obstructive pancreatitis 18.00 13.57 8 28946 882 79714552
Palpitations 17.84 13.57 92 28862 126518 79588916
Nasopharyngitis 17.21 13.57 42 28912 253839 79461595
Biliary colic 17.06 13.57 13 28941 3949 79711485
Pancreatic neuroendocrine tumour 16.71 13.57 7 28947 668 79714766
Blood glucose fluctuation 16.61 13.57 16 28938 6666 79708768
Hepatic steatosis 16.57 13.57 40 28914 37698 79677736
Infection 16.37 13.57 40 28914 241672 79473762
Blood ketone body increased 16.26 13.57 7 28947 715 79714719
Product quality issue 16.01 13.57 37 28917 33903 79681531
Lower respiratory tract infection 16.01 13.57 14 28940 129206 79586228
Gastrointestinal haemorrhage 16.00 13.57 18 28936 147701 79567733
Imminent abortion 15.94 13.57 3 28951 12 79715422
Helicobacter infection 15.92 13.57 3 28951 69701 79645733
Diabetic neuropathy 15.67 13.57 15 28939 6201 79709233
Extrasystoles 15.20 13.57 16 28938 7403 79708031
Diabetic ketosis 15.17 13.57 6 28948 494 79714940
Electrocardiogram QT prolonged 15.01 13.57 7 28947 90379 79625055
Urogenital infection fungal 14.79 13.57 3 28951 19 79715415
Somnambulism 14.79 13.57 14 28940 5707 79709727
Dysgeusia 14.72 13.57 50 28904 57127 79658307
General physical health deterioration 14.67 13.57 51 28903 275187 79440247
Device malfunction 14.36 13.57 27 28927 21421 79694013
Supraventricular extrasystoles 14.20 13.57 15 28939 6972 79708462
Pancytopenia 14.14 13.57 24 28930 165721 79549713
Anti factor V antibody positive 14.07 13.57 3 28951 25 79715409
Hyperchlorhydria 14.06 13.57 9 28945 2070 79713364
Medication error 13.61 13.57 4 28950 68638 79646796

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10AE56 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
INSULINS AND ANALOGUES
Insulins and analogues for injection, long-acting
ATC A10BJ02 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Glucagon-like peptide-1 (GLP-1) analogues
FDA CS M0160181 Glucagon-Like Peptide 1
FDA MoA N0000020058 Glucagon-like Peptide-1 (GLP-1) Agonists
MeSH PA D006728 Hormones
MeSH PA D007004 Hypoglycemic Agents
MeSH PA D054795 Incretins
FDA EPC N0000178480 GLP-1 Receptor Agonist
CHEBI has role CHEBI:63726 neuroprotective agents
CHEBI has role CHEBI:71196 GLP-1 receptor agonist

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Weight loss indication 89362005
Disorder of thyroid gland contraindication 14304000 DOID:50
Multiple endocrine neoplasia, type 2 contraindication 61808009
Pancreatitis contraindication 75694006 DOID:4989
C-cell hyperplasia of thyroid contraindication 237552009
Hypoglycemic disorder contraindication 237630007
Medullary thyroid carcinoma contraindication 255032005 DOID:3973
Pregnancy, function contraindication 289908002
Breastfeeding (mother) contraindication 413712001




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.06 acidic
pKa2 3.31 acidic
pKa3 3.67 acidic
pKa4 3.82 acidic
pKa5 4.11 acidic
pKa6 4.44 acidic
pKa7 9.65 acidic
pKa8 11.84 acidic
pKa9 12.2 acidic
pKa10 12.53 acidic
pKa11 12.59 acidic
pKa12 12.81 acidic
pKa13 12.86 acidic
pKa14 12.94 acidic
pKa15 13.1 acidic
pKa16 13.15 acidic
pKa17 13.2 acidic
pKa18 13.29 acidic
pKa19 13.43 acidic
pKa20 13.56 acidic
pKa21 13.56 acidic
pKa22 13.6 acidic
pKa23 13.71 acidic
pKa24 13.82 acidic
pKa25 13.82 acidic
pKa26 13.96 acidic
pKa27 13.97 acidic
pKa28 11.05 Basic
pKa29 10.45 Basic
pKa30 7.87 Basic
pKa31 5.98 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
18MG/3ML (6MG/ML) VICTOZA NOVO NORDISK INC N022341 Jan. 25, 2010 RX SOLUTION SUBCUTANEOUS 9968659 Jan. 9, 2037 METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, AND/OR NON-FATAL STROKE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE BY ADMINISTERING LIRAGLUTIDE
18MG/3ML (6MG/ML) SAXENDA NOVO N206321 Dec. 23, 2014 RX SOLUTION SUBCUTANEOUS 9968659 Jan. 9, 2037 CARDIOVASCULAR OUTCOMES TRIAL OF LIRAGLUTIDE 1.8 MG IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
18MG/3ML (6MG/ML) SAXENDA NOVO N206321 Dec. 23, 2014 RX SOLUTION SUBCUTANEOUS Dec. 4, 2023 NEW PATIENT POPULATION

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glucagon-like peptide 1 receptor GPCR AGONIST EC50 10.20 WOMBAT-PK CHEMBL

External reference:

IDSource
D06404 KEGG_DRUG
4029703 VANDF
C1456408 UMLSCUI
CHEBI:71193 CHEBI
CHEMBL4084119 ChEMBL_ID
CHEMBL4524066 ChEMBL_ID
D000069450 MESH_DESCRIPTOR_UI
DB06655 DRUGBANK_ID
1133 IUPHAR_LIGAND_ID
8208 INN_ID
839I73S42A UNII
16134956 PUBCHEM_CID
1598264 RXNORM
166619 MMSL
232503 MMSL
26647 MMSL
d07466 MMSL
010773 NDDF
444828003 SNOMEDCT_US
444907006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Saxenda HUMAN PRESCRIPTION DRUG LABEL 1 0169-2800 INJECTION, SOLUTION 6 mg SUBCUTANEOUS NDA 28 sections
Saxenda HUMAN PRESCRIPTION DRUG LABEL 1 0169-2800 INJECTION, SOLUTION 6 mg SUBCUTANEOUS NDA 28 sections
Saxenda HUMAN PRESCRIPTION DRUG LABEL 1 0169-2800 INJECTION, SOLUTION 6 mg SUBCUTANEOUS NDA 28 sections
Xultophy 100/3.6 HUMAN PRESCRIPTION DRUG LABEL 2 0169-2911 INJECTION, SOLUTION 3.60 mg SUBCUTANEOUS BLA 27 sections
Xultophy 100/3.6 HUMAN PRESCRIPTION DRUG LABEL 2 0169-2911 INJECTION, SOLUTION 3.60 mg SUBCUTANEOUS BLA 27 sections
Xultophy 100/3.6 HUMAN PRESCRIPTION DRUG LABEL 2 0169-2911 INJECTION, SOLUTION 3.60 mg SUBCUTANEOUS BLA 27 sections
Victoza HUMAN PRESCRIPTION DRUG LABEL 1 0169-4060 INJECTION 6 mg SUBCUTANEOUS NDA 28 sections
Victoza HUMAN PRESCRIPTION DRUG LABEL 1 0169-4060 INJECTION 6 mg SUBCUTANEOUS NDA 28 sections
Victoza HUMAN PRESCRIPTION DRUG LABEL 1 0169-4060 INJECTION 6 mg SUBCUTANEOUS NDA 28 sections
Victoza HUMAN PRESCRIPTION DRUG LABEL 1 50090-2853 INJECTION 6 mg SUBCUTANEOUS NDA 28 sections
Victoza HUMAN PRESCRIPTION DRUG LABEL 1 50090-2853 INJECTION 6 mg SUBCUTANEOUS NDA 28 sections
Saxenda HUMAN PRESCRIPTION DRUG LABEL 1 50090-4257 INJECTION, SOLUTION 6 mg SUBCUTANEOUS NDA 28 sections
Victoza HUMAN PRESCRIPTION DRUG LABEL 1 50090-4503 INJECTION 6 mg SUBCUTANEOUS NDA 28 sections
Victoza HUMAN PRESCRIPTION DRUG LABEL 1 50090-4503 INJECTION 6 mg SUBCUTANEOUS NDA 28 sections